"At Entrada, we value intellectual curiosity and enjoy the challenge of fighting the good fight: waking up each day to advance our science one step closer to helping patients and their caregivers who deserve better treatments."

Novel Platform, Growing Intracellular Therapeutics Pipeline

Our proprietary Endosomal Escape Vehicle (EEV™) Platform is highly versatile and modular, designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index.

Our novel approach is designed to address challenges associated with current therapeutics and engage targets previously considered inaccessible and undruggable. Explore our platform and discover our robust pipeline of discovery to clinical-stage programs.

At Entrada, our approach to corporate social responsibility is built upon our collective commitment to prioritize programs that provide public benefit, advance medical treatments and improve patient outcomes. We are driven to discover, develop and commercialize life-changing medicines that are safe, effective and accessible to those who need them.

We understand that different experiences and perspectives fuel innovation. This is why we are fostering a culture and workplace environment where everyone's voice is heard, and every individual belongs. Our collective success relies on it.

Creating an organization where diversity flourishes and our employees can belong takes ongoing attention and effort – and we know we can’t do it alone. We are proud to actively partner with organizations across Boston, Cambridge and the biotech sector. They provide community and mentorship while challenging the status quo so that we can learn, grow and improve the future for all.

The link you have selected will take you to a site outside Entradatx.com

Entrada does not review or control the content of any non-Entrada site. Entrada does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Entrada sources.

Thank you for your interest in Entrada Therapeutics!

The link you have selected will take you to a site outside Entradatx.com. We partner with Greenhouse to support our hiring process, and you are now transitioning to their website in order to apply. Entrada does not have control over the administration of Greenhouse.io. For further details, please view our privacy policies separately.

"Building a company like Entrada which was founded on pioneering science in the field of intracellular biologics, while being afforded an opportunity to potentially improve the lives of patients and their families, is an extraordinary privilege."

Nate is President and Chief Operating Officer of Entrada Therapeutics and is responsible for strategic planning, business development, portfolio management, and general operations. Nate joined Entrada as Chief Operating Officer in 2019 with almost 30 years of strategy, investment and operational experience in the healthcare sector. He was promoted to President and Chief Operating Officer in 2024.

Nate was previously Senior Vice President for Corporate Development at Rubius Therapeutics and prior to that he was in Managing Director roles at the Huron Consulting Group and The Frankel Group LLC advising biotechnology, biopharmaceutical, diagnostic and medical device companies. Nate also worked at Ernst & Young advising hospital systems and managed care companies, and at Searle Pharmaceuticals (now part of Pfizer), and CIGNA Healthcare.

Nate holds an MBA from the Booth School of Business at the University of Chicago and a BS from the University of Connecticut.

"What has us excited at Entrada is the versatility of our approach to intracellular therapeutics, and the potential to reach targets that have long been considered inaccessible. We see its potential across multiple diseases and we’re advancing the development of differentiated treatments that meet the significant unmet clinical needs of today."

Natarajan joined Entrada Therapeutics as Chief Scientific Officer in 2017. He leads research, and the clinical development and operations of the company’s intracellular therapeutics pipeline that is aimed at multiple neuromuscular, ocular, metabolic and immune mediated diseases, among others.

Natarajan brings to Entrada deep and broad experience in drug discovery and development with different modalities including oligonucleotides, antibodies, therapeutic enzymes, and peptides at start-up biotech and large-scale biopharma.

Prior to Entrada, Natarajan was at Merck & Co., Inc. for 10 years leading the GlycoFi site and the research and development of novel biologics. He joined Merck in 2006 with the acquisition of GlycoFi. Prior to that, Natarajan was Senior Scientist at Medical Enzymes for 11 years where he led the end-to-end development of drug candidates aimed at cancer and viral diseases.

Natarajan holds a PhD in Entomology, Molecular Biology and Biochemistry from the Indian Agricultural Research Institute, a BSc from Tamil Nadu Agricultural University and completed his post-doctoral training at Duke University.

"Entrada is uniquely positioned as a leader developing intracellular therapeutic solutions that address devastating diseases. Ensuring Entrada maintains a strong financial foundation is key to our ability to deliver on our mission and the opportunity to serve the unmet needs of patients."

Kory is Chief Financial Officer and Treasurer of Entrada Therapeutics and oversees finance, business services, and information technology for the company.

Kory joined Entrada in 2020 and brings over 15 years of experience in the biotechnology sector and a passion for developing successful teams known for integrity and delivering high quality results and insightful analysis. Kory has led both commercial and clinical stage companies through high growth, global product launches, operational scale, and financial strategies.

Kory was previously Vice President of Finance and Treasurer, and Principal Accounting Officer, at bluebird bio, Inc. with responsibilities for global accounting and reporting, treasury, tax, and accounting operations. He has also held senior finance positions at Alexion Pharmaceuticals and consulting roles in PricewaterhouseCoopers LLP’s assurance and business advisory practice.

Kory has a BS in Accounting from Susquehanna University and is a Certified Public Accountant.

"At Entrada, our culture is anchored in three pillars: belonging, contribution, and growth. This coupled with our passion for science, our dedication to patients, and our values will enable us to make intracellular therapeutics a reality."

Kerry is Senior Vice President, People at Entrada Therapeutics with responsibility for talent and organizational strategy supporting the company’s growth, defining its culture, and building its human resources strategy.

Kerry joined Entrada in 2020 from Sage Therapeutics where she led human resources strategy for talent management and organizational development. Prior to that, Kerry held leadership roles in human resources strategy, organizational development, employee engagement, leadership development, operations, DEI, and employee experience at Velir, a digital agency, and at Partners Healthcare (now Mass General Brigham).

Kerry holds an MS in Counseling Psychology from Northeastern University and a BS in Psychology from The George Washington University. Kerry previously served on the Board of the Boys & Girls Club of Middlesex County.

"Our company is guided by strong leadership, commitment to patients, and transparent science. It’s fundamental to who we are at Entrada and to our pursuit of developing new therapeutics that could change the lives of patients and their families."

Jared is General Counsel of Entrada Therapeutics. He leads the company’s legal, intellectual property, corporate governance, and compliance functions, and serves as Corporate Secretary.

Jared joined Entrada in 2020 from Repertoire Immune Medicines where he was Vice President of Legal Affairs with responsibilities for the legal, compliance, and intellectual property functions. Prior to that, Jared held senior legal roles of increasing responsibility at biotechnology and pharmaceutical companies including Alexion Pharmaceuticals, The Jackson Laboratory, MedImmune (now part of AstraZeneca), and Human Genome Sciences (now part of GSK). He is a former associate at Finnegan, Henderson, Farabow, Garrett & Dunner LLP.

Jared holds a BS in biology from Duke University, a PhD in Biochemistry, Molecular and Cell Biology from Cornell University, and a JD from Cornell Law School.

"Entrada's a special company with a strong commitment to patients, scientific excellence, and cultural belonging. Every day, we’re following the science to advance our near-term pipeline of treatments for people living with neuromuscular diseases and our longer-term treatment goals in other diseases."

Karla is Chief Corporate Affairs Officer of Entrada Therapeutics with responsibilities for building and amplifying the company’s brand through corporate communications, investor relations, government affairs and employee engagement. Karla also oversees Entrada’s patient advocacy team and champions the company’s steadfast commitment to patient-focused drug development.

Karla joined Entrada in 2021 from Ipsen Pharmaceuticals where she established and led corporate communications and patient advocacy for the company’s expansion into North America. Prior to Ipsen, she was at Merck & Co., Inc. where for over 11 years she led a broad spectrum of R&D, global brand and corporate responsibility communications and contributed to the R&D division as a member of the executive leadership team. Karla was previously in the healthcare practice at Ogilvy and MacDougall Biomedical and led investor relations for Creative BioMolecules.

Karla holds a bachelor’s degree in Education and a diploma in Communications from McGill University. Karla is a Board Member of the Canadian Entrepreneurs in New England and a Lead Mentor with the Canadian Technology Accelerator.

"Entrada’s pipeline of intracellular therapeutics has the potential to treat a broad range of serious diseases; we embrace the responsibility to efficiently advance development and potentially transform the lives of patients and their families."

Kevin is Senior Vice President of Regulatory Affairs and is responsible for implementing global regulatory strategies to advance the company’s pipeline of oligo-, antibody- and enzyme-based intracellular programs spanning discovery and clinical development.

With extensive expertise in the development and commercialization of therapies for serious and rare diseases, Kevin has led or participated in more than 30 formal meetings with the FDA, EMA, and other global health authorities.

Prior to Entrada, Kevin oversaw Regulatory Affairs at Enzyvant Therapeutics, Roivant Sciences, and Mallinckrodt Pharmaceuticals. His experiences, including earlier career work at Gilead Sciences, focused on efficiently developing and executing global strategies from discovery through commercialization for biologics and small molecule therapies.

Kevin holds a PhD in Biochemistry from the University of Wisconsin-Madison and a BS in Biological Sciences from Cornell University.

Kush M. Parmar, MD, PhD, is a Managing Partner at 5AM Ventures.

Kush M Parmar, MD, PhD is a Managing Partner at 5AM Ventures. Dr. Parmar is a Director on the Boards of Akouos, Ensoma, GlycoEra, Rallybio and Vor Biopharma. He previously served as Board Member or Observer for Achaogen, Arvinas, Audentes, Envoy (acquired by Takeda), Homology and scPharmaceuticals and as Acting VP of Strategy and Corporate Development at Novira (acquired by J&J).

Dr. Parmar serves on the Advisory Boards of Harvard Medical School, Penn Medicine, Princeton University’s Department of Molecular Biology and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows. Prior to 5AM, Dr. Parmar was at Harvard Medical School, where he was an NIH-sponsored MD/PhD Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. He completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals. At Princeton University, Dr. Parmar worked on developmental genetics with Eric F. Wieschaus (Nobel Prize in Medicine in 1995).

Dr. Parmar holds an AB in Molecular Biology and Medieval Studies from Princeton University, a PhD in Experimental Pathology from Harvard University and an MD from Harvard Medical School.

Peter S. Kim, PhD, is the Virginia and D.K. Ludwig Professor of Biochemistry at Stanford University, Institute Scholar at Stanford ChEM-H, and Lead Investigator of the Infectious Disease Initiative at the Chan Zuckerberg Biohub.

Dr. Kim is a pioneering scientist with over 30 years of experience in both academia and the biopharmaceutical industry and has unmatched experience taking groundbreaking products from bench to bedside. Dr. Kim was President of Merck Research Laboratories (MRL) from 2003 to 2013, where he oversaw Merck's global drug and vaccine research and development activities. During his tenure at MRL, Dr. Kim oversaw the approval of more than 20 new medicines and vaccines. Prior to his time at Merck, Dr. Kim was a Professor of Biology at Massachusetts Institute of Technology and a Member of The Whitehead Institute. There he conducted seminal research elucidating the way in which proteins enable viral membranes to fuse with cells.

Dr. Kim’s exceptional record of scientific achievement has resulted in his election to the National Academy of Sciences, the National Academy of Medicine, the National Academy of Engineering, the American Academy of Arts and Sciences and the Korean Academy of Science and Technology. Dr. Kim is also a Fellow with the American Association for the Advancement of Science, the American Academy of Microbiology and the Biophysical Society. As an advisor to 5AM Ventures Dr. Kim was one of the first scientists to recognize the potential of the EEV™ platform.

Gina Chapman is President and CEO of CARGO Therapeutics, a clinical-stage biotechnology company positioned to advance next generation CAR T-cell therapies.

Ms. Chapman brings more than 30 years of biopharmaceutical commercial and operational experience across numerous therapeutic areas, with a track record of success shaping strategy, building teams and driving results. As President and CEO of CARGO Therapeutics, Ms. Chapman is leading the company’s development of next-generation CAR T-cell therapies that address multiple mechanisms of resistance to deliver therapies to people living with cancer.

Prior to joining CARGO, Ms. Chapman spent 15 years at Genentech where she served as Senior Vice President, Business Unit Head and was responsible for delivering the P&L across the oncology, hematology, neurology, immunology, ophthalmology, respiratory and rare diseases business units. Ms. Chapman began her biopharma career with Syntex Laboratories and in 1994 she joined Gilead Sciences as one of the first commercial hires where she was responsible for the launch of the company’s first commercial medicine and was a key contributor during its rapid growth from clinical stage start-up to commercial enterprise.

Mary Thistle is an industry leader and independent director.

Ms. Thistle has a 25+ year track record of creating shareholder value through financial, strategy, business development and commercial leadership across a range of therapeutic areas, including a deep background in rare diseases. She also serves on the Board of Directors of Alaunos Therapeutics, Vigil Neuroscience, Enterome and Homology Medicines, as well as several private companies.

Ms. Thistle previously served as Chief of Staff and Special Advisor to the Bill & Melinda Gates Medical Research Institute where she led the establishment of the non-profit biotech organization. Prior to that, Ms. Thistle was Chief Operating Officer of Dimension Therapeutics where she oversaw the company's Series B financing and initial public offering, expanded the pipeline through strategic business development transactions and led the sale of the company to Ultragenyx. Prior to Dimension, Ms. Thistle was Senior Vice President, Business Development at Cubist Pharmaceuticals, where she was responsible for multiple acquisitions and assisted in the sale to Merck. She has also held senior level positions at ViaCell in finance, operations and business development and served as Senior Vice President, Business Development at PerkinElmer after ViaCell was acquired.

Ms. Thistle began her career as a Certified Public Accountant and holds a B.S. in Business and Accounting from the University of Massachusetts.

Bernhardt “Bernie” Zeiher, MD, is an industry leader and independent director.

Dr. Zeiher has over 20 years of experience in the pharmaceutical industry, participating in the development and approval of 15 products across multiple therapeutic areas. As an Entrada board member, Dr. Zeiher provides both clinical and regulatory insights as the company continues to advance our lead programs. He has served on the Board of Directors for TransCelerate BioPharma Inc. from 2014 to 2022.

Dr. Zeiher was most recently the Chief Medical Officer at Astellas Pharma. He started at the company in 2010 as Vice President and Therapeutic Area Leader for Inflammation, Immunology and Infectious Diseases. He was promoted to Senior Vice President and Therapeutic Area Head for Immunology, Infectious Diseases and Transplant in 2012. Dr. Zeiher was later named Executive Vice President and Therapeutic Area Head when his responsibilities expanded to include the company's development operations and clinical pharmacology departments. He was promoted to President of Development in 2015, and Chief Medical Officer in 2018. Prior to joining Astellas, Dr. Zeiher served as Vice President of the Inflammation and Immunology Therapeutic Area at Pfizer and Medical Director for Inflammation and Immunology at Eli Lilly.

Dr. Zeiher received a BS in Biology from the University of Toledo, earned his Doctor of Medicine at the Case Western Reserve University School of Medicine, and completed an internal medicine residency at University Hospitals of Cleveland as well as a fellowship in Pulmonary and Critical Care Medicine at University of Iowa Hospitals and Clinics. He served on the Board of Directors for the Biotechnology Innovation Organization (BIO) from 2019 to 2021. Dr. Zeiher is a Fellow in the American College of Physicians and the American College of Chest Physicians, which is awarded to those who demonstrate knowledge and compassion towards teaching others.

"Everyone at Entrada is laser-focused on advancing our intracellular therapeutics pipeline knowing our EEV™ therapeutics have the potential to change the way incurable diseases are treated and transform the lives of patients and families."

Dipal has been Chief Executive Officer of Entrada Therapeutics and a Member of the Board of Directors since joining Entrada in 2017 as its first full-time employee shortly after the Company was founded and funded with seed capital. He previously served as President and Chief Executive Officer from 2017 to 2023.

Dipal has led many critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning, and finance. Prior to joining Entrada, Dipal was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. He has also held senior level positions at Auven Therapeutics, a healthcare private equity fund, and at Catalent Pharma Solutions (now Catalent). Earlier in his career, Dipal worked in Merrill Lynch's Investment Banking Group and held several roles at Eli Lilly and Company.

Dipal holds an MBA from The Wharton School of the University of Pennsylvania and a BA from Rutgers University. Dipal is a Fellow of the Aspen Institute and on the Board of Advisors of Life Science Cares Boston.